LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1

Triple-negative breast cancer (TNBC) is a highly metastatic breast cancer subtype and due to the lack of hormone receptors and HER2 expression, TNBC has limited therapeutic options with chemotherapy being the primary choice for systemic therapy. LIM Domain Kinase 2 (LIMK2) is a serine/threonine kina...

Descripción completa

Detalles Bibliográficos
Autores principales: Malvi, Parmanand, Janostiak, Radoslav, Chava, Suresh, Manrai, Padmini, Yoon, Esther, Singh, Kamaljeet, Harigopal, Malini, Gupta, Romi, Wajapeyee, Narendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455732/
https://www.ncbi.nlm.nih.gov/pubmed/32859889
http://dx.doi.org/10.1038/s41389-020-00263-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455732/
https://www.ncbi.nlm.nih.gov/pubmed/32859889
http://dx.doi.org/10.1038/s41389-020-00263-1

Ejemplares similares